Drug Trial Radar · NCT07064525
Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension
Last checked: Nov 19, 2026Latest source record: Jul 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
252
Planned (sponsor's estimate)
Start
Dec 5, 2024
Primary completion
Dec 15, 2025
Study completion Feb 28, 2026
Sponsor
- Lead sponsor
- Shin Poong Pharmaceutical Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
\- Objective: This study aims to evaluate the safety and efficacy of the fixed-dose triple combination therapy (SPC1001 Low) of candesartan, amlodipine, and indapamide in adult patients with essential hypertension compared to dual-component therapies of each ingredient for 8 weeks. Additionally, it seeks to confirm the contribution of each component at low doses. \- Inclusion Criteria: Men and women aged 19 to 75 years whose blood pressure measured at the screening visit meets the following criteria. \- Exclusion Criteria: Patients whose blood pressure measured at the screening and randomization visits meets the criteria of MSSBP ≥180 mmHg or MSDBP ≥110 mmHg, among other conditions. \- Methods: This study is a multicenter, randomized, double-blind, parallel-group, phase 2b clinical trial to evaluate the safety and efficacy of the investigational drug after 8 weeks of administration. Screening assessments will be conducted within 4 weeks prior to randomization, and patients who meet the inclusion and exclusion criteria at the screening visit will be enrolled in the study after providing informed consent. These participants will undergo a 2-week run-in period during which they will take a placebo and participate in a lifestyle modification program.
Conditions
- Hypertension (HTN)
- NYHA Class III Heart Failure
- NYHA Class IV Heart Failure
- Diabete Mellitus
Interventions
SPC1001 LowDrug
low-dose combination therapy
SPC5002Drug
low-dose combination therapy
SPC5003Drug
low-dose combination therapy
SPC5004Drug
low-dose combination therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary endpoint was determined by evaluating how mean sitting systolic blood pressure varied between the baseline measurement and week 8Time frame: change in MSSBP from baseline at week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CHA Gangnam Medical Center, CHA University
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.